April 6, 2020

Dear Journal of Clinical Immunology (JoCI) Authors, Reviewers, and Readers:

The Co-Editors-in-Chiefs, Associate Editors and Editorial board, of The Journal of Clinical Immunology extend our best wishes for your and your family’s safety, and the research and clinical immunology professional communities. We recognize the extraordinary challenges that the SARS CV2 (CVID-19) pandemic has imposed on research investigators and the clinicians who care for patients with primary immunodeficiency. We also appreciate that these are trying times in which to keep research efforts going, and in meeting publication resubmission deadlines.

For our authors with manuscripts that require substantial revision, we recognize that laboratory closures have disrupted your research efforts, and that this will limit your ability to respond to the JoCI reviewers’ comments. You may wish to contact us as Co-Editor-In-Chiefs of the JoCI to discuss which revisions can be accomplished during this time of unprecedented laboratory closures. We will prioritize reviewer comments to reduce the need for additional experiments, where possible, and still preserve the scientific integrity of the review process.

To address concerns about prioritizing the most important reviewer comments, you can send an email to the Co-Editors-In-Chiefs thought the JoCI website (https://www.springer.com/journal/10875/contact-the-journal), to Britta Müller (britta.mueller@springer.com). In addition, the resubmission deadline will be indefinitely postponed depending on your agreement established with the Co-Editor-In-Chief who is handling your manuscript.

For our reviewers, we understand that there may be delays in returning a review. If you need more time to complete your review, or need to decline an assignment, please contact the JoCI editorial office as soon as possible at the following e-mail address: Carlo Baco (carlo.baco@springernature.com). The JoCI staff stands ready to assist you in any way possible and can be reached at the e-mail addresses above.

We support and understand the frustration that surrounds publication of important advances in the field that are to be published in the JoCI during these trying times. We salute the thousands of dedicated scientists who continue to pursue their research and our reviewers who help with the peer review process during this crisis. We are particularly grateful to our primary immunodeficiency physician scientists who are on the
frontlines of this pandemic serving the international needs of children and adults with primary immunodeficiency disease.

From all of us who comprise the entire JoCI editorial board, and the Springer Staff that supports the publication of the JoCI, we thank you.

Sincerely,

Vincent R. Bonagura MD   Jean Laurent Casanova MD PhD
Co-Editor-in-Chief JoCI   Co-Editor-In-Chief JoCI

Britta Müller PhD
Senior Publishing Editor